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Abstract. 
Scaffolding proteins organize the information flow from activated G protein-coupled 
receptors (GPCRs) to intracellular effector cascades spatially and temporally. By this 
means signaling scaffolds such as A-kinase anchoring proteins (AKAPs) 
compartmentalize kinase activities and ensure substrate selectivity. Using a phospho-
proteomics approach we identified a physical and functional connection between protein 
kinase A (PKA) and GPR161 signaling. We show that the orphan GPCR GPR161 on its 
own contains the structural features to function as high-affinity type I AKAP. Binary 
complex formation affects plasma membrane targeting in cells and provokes GPR161-
mediated PKA recruitment into the primary cilium of zebra fish embryos. We illustrate that 
receptor-anchored PKA complexes enhance cAMP-mediated GPR161 phosphorylation, 
which is regarded as one general principal for regulating GPCR desensitization. In 
addition, we unveiled that distinct disease mutations of PKA regulatory subunits 
differentially contribute to spatially restricted interactions of GPR161-anchored PKA type 
I holoenzyme complexes. Thus, the integrity of the membrane-targeted and cAMP-
sensing GPR161:PKA signalosome needs to be considered in analyzing, interpreting, and 
pharmaceutical targeting of GPR161-involved and PKA-associated human diseases.  
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Introduction  
Scaffolding proteins act as flexible organizing centers to consolidate and propagate 
the cellular information flow from activated cell-surface receptors to intracellular effector 
cascades. Activated G protein-coupled receptors (GPCRs) engage pleiotropic scaffolds 
such as beta-arrestin and A-kinase anchoring proteins (AKAPs) to recruit cytoplasmic 
downstream effector molecules1-5. Thus compartmentalized GTPases, kinases and 
phosphatases act as GPCR-linked molecular switches to spatially and temporally control 
signal propagation. In the classical view of GPCR signaling, extracellular ligands bind to 
the receptor which catalyzes the intracellular GDP/GTP exchange and activation of 
receptor-associated trimeric G protein () combinations3. In addition to receptor 
dimerization, GPCR signaling and trafficking involve G protein-dependent and G protein-
independent intracellular interactions with scaffolds such as beta-arrestin and AKAPs1, 2, 
6, 7. Receptor-interacting proteins and kinase activities contribute to the fine-tuning of 
GPCR localization and activities5, 8-10. Different AKAPs coordinate and compartmentalize 
diffusible second messenger responses through anchoring of cAMP-dependent type I or 
type II protein kinase A (PKA) holoenzymes, composed of two regulatory (RIor RII) 
and two catalytic (PKAc) subunits, to discrete subcellular localizations11. The four R 
subunits have different expression patterns and are functionally non-redundant. The 
growing family of AKAPs are functionally diverse; however, all AKAPs contain an 
amphipathic helix, which account for nano-molar binding affinities to PKA R subunit 
dimers12, 13. Moreover, it has been shown that additional components of the cAMP 
signaling machinery physically interact with AKAPs, such as GPCRs, adenylyl cyclases 
(ACs) and phosphodiesterases (PDEs)1, 6, 14-16. Deregulation of the GPCR-cAMP-PKA 
pathways contribute to a variety of human diseases. Mutations in different PKA subunits 
manipulate PKA dynamics and activities and contribute to specific disease patterns. 
Mutations activating cAMP/PKA signaling contribute e.g. to carcinogenesis or 
degenerative diseases, while inactivating mutations cause e.g. hormone resistance17-27. 
Therefore, revealing the composition of signaling complexes formed upon GPCR and 
kinase activation is critical for understanding the modes of kinase activation. In-depth 
analyses of transient protein:protein interactions (PPIs) along with the phosphorylation 
dynamics have the potential to reveal conditional signal flow and thus may help to explain 
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pathological implications of second-messenger signaling. Such a strategy will lead to a 
better understanding of cAMP-signaling, which boosts proliferation in many cell types but 
inhibits cell growth in others28-31. Using a proteomics approach we have identified a 
physical and functional interaction of an orphan GPCR with distinct PKA subunits. We 
demonstrate that GPR161 is both a type I AKAP and a PKA substrate. 
 
Results. 
Protein:protein interaction (PPI) information is typically  generated in exogenous 
systems such as the yeast two-hybrid approaches  or from affinity purification followed by 
mass spectrometry of overexpressed tagged proteins32. Here, we affinity-purified 
endogenous PKA complexes from the osteosarcoma cell line U2OS after simulation of 
chronic stress conditions by selective activation of 2AR; a GPCR linked to cAMP-
mobilization and PKA activation10. We applied PKA-selective Rp-8-AHA-cAMP-agarose 
resin to isolate endogenous PKA complexes under varying ligand occupancies and 
timings of cAMP-generating ACs and endogenous AR from U2OS cells. Following 
proteomic and phospho-proteomic analyses (liquid chromatography - mass 
spectrometry), we generated an integrated PKA PPI network representing a consistent set 
of PKA associated proteins linked to PKA signaling: We confirmed the enrichment of all 
four PKA regulatory subunits (RI,RI, RII, RIIand two PKA catalytic subunits 
(PKAc). We organized the interaction partners in a fan-shaped pattern surrounding the 
centered PKA subunits providing a combined overview of 92 affinity-purified proteins 
using Rp-8-AHA-cAMP-resin (Supplementary Fig. 1&2; Supplementary Table 1; 
Supplementary information). However, to ease the selection of functionally linked PKA 
interactors we mapped all the detected phosphorylation sites and present co-purified 
phospho-proteins with their identified sites in a PKA centric illustration including 76 known 
phosphorylation and 33 potential PKA group phosphorylation sites (Fig. 1a). With the Rp-
8-AHA-cAMP  bound PKA subunits we co-precipitated the AKAPs 1,2,3,5,8,9&11, which 
are known binary interaction partners of R subunits, along with further components of the 
cAMP machinery (PDE4A, PDE4IP) and kinase signaling. We discovered that these 
AKAP-organized PKA complexes contain additional proteins involved in protein transport, 
RNA binding and discrete posttranslational modifications (e.g. HDAC6 and PRMT6). Our 
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analyses identified a large set of proteins attributed to metabolic signaling, thus 
underlining established and revealing novel connections of PKA to metabolic pathways. 
Interestingly, also not easy accessible interactors like membrane receptors and channels 
(e.g. GPR161, ADORA3 and TRPC3, KCNJ3) were identified in the macromolecular PKA 
complex. This observation prompted us to characterize an unforeseen physical link to a 
membrane protein, the orphan GPCR GPR161, which actually contains a canonical PKA 
phosphorylation consensus site in its carboxy-terminus (CT, ...427RRSS430…). This 
decision was endorsed by previous studies and observations: First, it has been previously 
shown that the GPR161-CT is critically implicated in developmental processes (lens 
development, neurulation) through implications in GPR161 localization (Fig. 1b)33. 
Second, both GPR161 and PKA activities are involved in hedgehog signaling in the 
primary cilium (Fig. 1b)34, 35. Third, a physical connection of PKAc with GPR161 has been 
proposed in a recent network study using tagged PKA subunits as bait36. Fourth, 
upregulated GPR161 expression patterns have been found in triple negative breast 
cancer37. This begs the questions how physical PKA associations with this orphan 
receptor (indirect or direct?) might contribute to GPR161 functions.  
To facilitate the analyses of the function of the cytoplasmic localized GPR161-CT 
(=CT342-529), we generated different glutathione-sepharose-transferase (GST) expression 
constructs to investigate complex formation with PKA. In GST pulldown assays we 
precipitated endogenous PKA subunits from HEK293 cell lysates with GST- CT342-529. We 
significantly enriched endogenous RI:PKAc complexes. No binding of RIIwas 
detectable. Addition of excess of cAMP to the precipitation reaction initiated PKA complex 
dissociation. In contrast to diminished PKAc binding, the GST-CT342-529:RI complex was 
insensitive to cAMP-binding (Fig. 1c). These data underline that binding of PKAc to 
GPR161 is mediated through RI subunits. To determine specific amino acids in GPR161 
that are responsible for RI binding we performed a peptide spotting experiment. We 
spotted overlapping 25-mer peptides derived from GPR161-CT342-529 sequence onto a 
membrane and overlaid it with recombinant RI-his6 (hexa-histidine tagged), as previously 
described38. In the GPR161-CT we identified one possible binding site for RI with the 
core region …LDSYAASLAKAIE… (Fig. 1d). This sequence stretch is part of an 
amphipathic helix with the centered Leu465 (Fig. 1e) which we substituted in the next 
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experiments for proline. With different recombinant GST-CT variants of GPR161 we 
repeated the pulldown experiments with recombinant RI in vitro. We confirmed the binary 
interaction of RI with wild type GPR161-CT342-529, and once again this complex is 
insensitive to cAMP binding to RI. All shorter variants of GPR161-CT which contain the 
core LAKAIE motif showed interaction with recombinant RI. The GST-CT342-529 mutant 
containing the L465P substitution showed no binding to RI (Fig. 2a). These experiments 
confirmed a binary PPI, GPR161-CT:RIin vitro. Moreover, it proved that an amphipathic 
helix in the GPCR-CT directly mediates PPI with type I PKA R subunits as it has been 
described in detail for all other members of the AKAP family.  
We next repeated the experiment with cell lysates. We observed a similar pattern 
of PPI with RI. Endogenous RII did not bind to any of the GST-fused CTs 
(Supplementary Fig. 3a). With overexpressed GPR161 variants we repeated cAMP-
precipitation experiments as performed for Fig. 1a and Supplementary Figs.1&2. We show 
that cAMP-bound R subunits are sufficient for the precipitation of full-length GPR161 
tagged with Venus YFP. In comparison, the GPT161-CT mutant (L465P) showed no PPI 
(Supplementary Fig. 3b). This data confirms our peptide array experiments and 
demonstrates that the CT mediates binary PPI with RI PKA subunits in cells.  
Next we tagged the CT378-529 N- and C-terminally with hexa-histidine tags (his6) to 
increase its solubility. In contrast to the CT378-529L465P mutant, sole expression of the wild 
type fusion protein in bacteria showed low solubility. However, following bacterial co-
expression of CT378-529 and untagged RI we observed enhanced solubility of the CT378-
529. Strikingly, in affinity purifications using Ni-NTA resin we co-purified significant amounts 
of untagged RI with CT378-529 ; we observed no PPI with the L465P mutant CT of GPR161 
(Fig. 2b). A subsequent cAMP-precipitation showed the stability and specificity of this 
binary PPI in vitro (Supplementary Fig. 4). The significant enrichment of RI with his6-
CT378-529his6 suggests that a ratio of CT:RIcomplexes of 1:2 is favored. This would 
underline the AKAP concept describing that one R subunit dimer interacts with the 
GPR161-AKAP helix. In dot blot analyses we compared binding of recombinant RI to 
amphipathic helices of selected AKAPs39. We observed that binding of RI also depends 
on the length and on the positioning of critical amino acids of the selected amphipathic 
helices. In this in vitro assay we confirmed specific binding of RItosequences 
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surrounding the LAKAIE motif; binding was abolished with peptides containing proline 
substitutions (Supplementary Fig. 5). To understand the specificity of GPR161-CT 
binding we analyzed the helical propensity of GPCR161-CT with Agadir, an algorithm that 
predicts the helical content of peptides40. The -helix is predicted to span from D459 to 
L477. The modified L465 is located in the middle of the helix (Supplementary Fig. 6a). 
In structure-based alignments of GPR161 with RI specific AKAPs and dual specific AKAPs 
we identified residues that are similar and bind the D/D domain hydrophobic groove 
(shown in red; Fig. 2c). RII specific AKAPs do not align the same way (Supplementary 
Fig. 6b). We present a structural model of RI-D/D domain in complex with GPR161 (457-
479), based on RI-D/D domain in complex with D-AKAP213. There are four conserved 
binding pockets in the D/D domain, each allowing two hydrophobic residues of the AKAP 
amphipathic helix to dock onto the hydrophobic groove (Fig. 2d). These hydrophobic 
residues are conserved in RI specific AKAPs (shown as surfaces in Fig. 2d). All other 
GPR161 specific residues, within the predicted helix, which do not align with other RI 
specific AKAPs and are solvent exposed (shown in cyan). Next, we subjected the 
corresponding peptide CT459-477 to fluorescence polarization measurements with full 
length RI or RII. We observed selective and high affinity binding of the peptide to RI 
with a Kd of 6.039 nM (±0.105). With RII homodimer we observed no binding (Fig. 2e). 
This is in agreement with the pulldown assays illustrated in Fig.1c und Supplementary Fig. 
3a showing exclusive RI binding to the different CTs. Assessments of AKAP sequences 
and the structural model with previously published RI and RII structures explains the 
selectivity for GPR161-CT binding to RI13, 41: The structure comparison of the D/D 
domains of RI and RII unveils a more extended hydrophobic surface at the N-terminus 
of RI that includes a third helix (0-Helix) instead of a short strand that is a conserved 
feature of RII subunits. Embedded within these RI-specific pockets are the disulfide bonds 
that are also a unique feature of RI D/D domains. Cys16A in the 0-Helix forms a disulfide 
bond with Cys36B. The disulfide bond stabilizes the N-terminus of the RI-subunits 
potentially allowing them to serve as redox sensor. In contrast, the RII subunits have only 
2 helices and no extra 0-Helix or cysteines in their D/D domains13. We also highlight in 
the sequence alignment shown in Fig. 2c s that the N and C terminus of the amphipathic 
helix of GPR161 provide additionally unique hydrophobic interactions. The red underlayed 
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Leucins of the GPR161 AKAP motif bury the RI D/D domain disulfide bonds thereby 
creating two additional pockets, one at each end. These two hydrophobic residues explain 
the preference of GPR161 for RI binding. These Leucines not only provide additional 
binding surfaces to the RI D/D domain but would also protect the RI disulfide bonds 
(Cys16-37) from the redox environment (Fig. 2f).   
To investigate the function of PKA:GPR161 interaction we analyzed the dynamics of 
receptor localization and phosphorylation. Fig. 3a depicts sequence elements in the 
GPR161-CT which we analyzed. As starting point we constructed mammalian expression 
vectors of different GPR161-variants tagged with Venus-YFP at the carboxy-terminus. We 
tested the consequence of general and GPCR-mediated cAMP-elevation on GPR161 
phosphorylation. We transiently overexpressed Venus-YFP tagged wild type receptor 
along with the S429A/S430A and L465P mutants in HEK293 cells stably expressing 2 
adrenergic receptors (2AR).  2AR are coupled to the stimulatory G protein s (Gs) and 
therefore are linked to cAMP elevation. We elevated cellular cAMP-levels with Forskolin 
and/or the AR ligand Isoproterenol. Following immunoprecipitation of the GPR161 
variants we tracked changes of the phosphorylation status of GPR161 variants with a 
general PKA substrate antibody. In contrast to the L465P mutant we showed that the 
overexpressed wild type and S429A/S430A receptor bind endogenous RI. Upon cAMP-
elevations we observed a significant elevation of GPR161 phosphorylation. With the 
GPR161-S429A/S430A mutant, however, we detected no phosphorylation signal at all, 
underlining that S429/S430 is the target for PKA phosphotransferase activities (Fig. 3b, 
Supplementary Fig. 7a). Moreover, the L465P receptor mutant - which does not 
compartmentalize PKA complexes - showed a significant reduction of GPR161 
phosphorylation following cAMP-elevation (Fig. 3b). The PKA mediated phosphorylation 
of GPCR-CT is regarded as one general principal of controlling GPCR desensitization8, 9, 
42, 43. Therefore, these data underline that the GPR161 compartmentalized type I PKA 
activities directly sense and integrate cAMP-oscillations which affect receptor 
phosphorylation and localization. To underline that the CT is critical for cellular 
GPR161:PKA complexes we used the Venus-YFP tagged receptor constructs for co-
precipitation studies. In immunoprecipitations of GPR161-wt we co-purified cAMP-
dependent PKA complexes. The GPR161-CT variant showed no PPI with PKA subunits 
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(Supplementary Fig. 7b). The same constructs were tested in localization studies. The 
wild type receptor and the S429A/S430A mutant were mainly localized to cytoplasmic 
compartments. In agreement with previous studies 33 the GPCR161 variant which lacks 
the CT (GPR161-CT) was primarily localized to the plasma membrane (Supplementary 
Fig. 7c). To ease co-localization studies with RI-GFP we tagged full length receptors at 
the carboxy terminus with mCherry. Following transient overexpression of the GPR161 
variants in single transfection studies we confirmed cytoplasmic accumulations of the 
receptor with all three used mutants. RI-GFP was found throughout the cytoplasma with 
highly specific speckled/punctuate localizations (Fig. 3c). Interestingly, upon co-
expression of the wt and SS429AA receptor the a proportion of the GPR161:RI complex 
was recruited to the plasma membrane. Strikingly, with the GPR161-L465P mutant we 
detected no co-localization nor membrane recruitment (Fig. 3d). These data underline an 
involvement of RI subunit binding in membrane targeting of GPR161.  
The involvement of GPR161 in cilium signaling has been shown previously. Therefore 
we determined the localization of GPR161:RI directly in Zebrafish embryos. We 
observed that overexpression of the mCherry tagged wild type GPR161initiated receptor 
mediated PKA recruitment into the primary cilium of zebra fish embryos. In the 
experiments with the L465P mutant we observed significantly less cilium staining of GFP 
tagged RI (Fig. 3e Pia your turn).  
Next we applied a Renilla luciferase (Rluc) based protein-fragment complementation 
assay (PCA) to confirm that binary GPR161:RI interactions are formed directly in the living 
cell (Fig. 4a). Besides quantification of RI homodimer formation we illustrate specific 
binding of RIα to GPR161 in HEK293 cells. With the GPR161-L465P mutant the PPI signal 
decreased significantly (Fig. 4b). To our surprise we also detected GPR161 dimerization 
using this cellular PPI reporter. Application of L465P mutants rather showed an increase 
of GPR161 dimers. However, the functional consequence of this observation needs to be 
evaluated. As predicted we observed that elevation of cAMP-levels triggered PKA 
complex dissociation of RI:PKAc. We could not detect a major impact of cAMP elevation 
on the GPR161:RI complex (Supplementary Fig. 8). We also wanted to test how far 
disease mutations of RI and RI affect the complex formation with the AKAP GPR161. 
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Through the N terminal dimer and docking domain, R subunit dimerizes and interacts with 
amphipathic helices of AKAPs14, 44. Therefore a perturbation of the integrity of the dimer 
and docking region would specifically affect AKAP interaction. Recently the patient 
mutation L50R in the D/D region of RIβ has been associated with a neurodegenerative 
disorder causing accumulations of RIβ in neuronal inclusions27. Using the Rluc PCA 
reporter we showed that RI specifically binds to GPR161. Application of the RIβ[L50R] 
mutant significantly decreased RIβ homo-dimerization (Fig. 4c). It is the amino acid 
substitution directly in the antiparallel four helix bundle in the dimer/docking of RI dimers 
which is responsible for complex disruption. Dimer formation of R subunits is also a 
precondition for AKAP binding. In the Rluc PCA measurements we observed a substantial 
reduction of RIβ[L50R]:GPR161 complexes (Fig. 4c). This experiment further underlines 
that GPR161 acts as type I AKAP. Next, we also wanted to test a link to better 
characterized patient mutations in the PRKAR1A gene. A collection of RI mutations have 
been linked to distinct disease phenotypes17, 20, 24-26, 45-50. In the recent years a growing 
number of RIdisease mutations from Acrodysostosis and Carney complex patients 
have been made public.  In contrast to perturbations of R dimerization, the tested RI 
mutations either affect cAMP binding or - in the case of the Carney complex mutant R74C 
- the mode of action is still controversial. We quantitatively evaluated the impact of all 
three RI mutations by analyzing complex formation with GPR161. We showed that 
neither the Carney complex mutation (R74C) nor the Acrodysostosis mutations (R335P, 
R368X) significantly changed the complex formation with GPR161 (Fig. 4d). This 
underlines that the GPR161:RI complexes are formed despite the mutations. However, 
what is the functional consequence of mutational perturbation of cAMP nucleotide binding 
domain B (CNBB)? Using the Rluc PCA as read out we showed that the RI[R335P] 
mutated PKA type I complex (which actually still interacts with GPR161) is less responsive 
to beta-adrenergic receptor initiated cAMP-elevations (Fig. 4d). The R335P mutation is 
sufficient to impair the cAMP-dependent dissociation of PKAc from RI. These data 
underline that GPR161 binds mutated RI holoenzyme complexes which are less reactive 
to cAMP controlled PKA activation. We assume that in a pathological cell setting such 
GPR161-anchored PKA complexes would be insensitive to transient cAMP-elevations 
thereby reducing or preventing PKA substrate phosphorylation.  
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Conclusion. 
The idea that scaffolding proteins act as organizing centers to converge and 
redirect the information flow has evolved during the last two decades4, 7. Diverse scaffolds 
assemble flexible signaling nodes consisting of GTPases, kinases and phosphatases 
spatially and temporally. In the classical view scaffolds like the AKAP family, beta-arrestin, 
Ksr1 or PSD-proteins act as flexible connecting pieces between receptors and 
downstream effectors 1, 2, 4, 51. Here we illustrate that one orphan GPCR by itself contains 
all the structural features that allow to be a high affinity anchoring protein (AKAP) for type 
I PKA. Several examples how selective AKAPs recruit type II PKA to distinct membrane 
receptors have been illustrated14, 52, 53 54. Here we present the discovery of a binary 
receptor-kinase interaction which opens new possibilities for anchoring and receptor-
mediated compartmentalization of PKA contribute to physiological but also pathological 
receptor and kinase functions. This demonstrates that PKA type I compartmentalization 
is essential for efficient receptor phosphorylation which is a general principle for controlling 
receptor desensitization8, 9, 42, 43. An additional function of the binary GPR161-PKA 
interaction is the targeting of receptor-kinase complexes to the plasma membrane. The 
mode of action is still elusive. Interestingly, in a recent study GPR161 expression levels 
have been correlated with aberrant proliferation in triple negative breast cancer cells37. 
This observation and our findings that exclusively type I PKA regulatory subunits (RI) 
bind to the membrane receptor motivated us to test GPR161 interactions with mutated 
and disease relevant RI subunits. Several genetic defects in distinct PKA subunits have 
been revealed. Both kinase inactivating and activating mutations have been described. 
Besides dysfunctions of phosphotransferase activities of PKAc which are linked to 
Cushing’s syndrome and hepatocellular carcinoma 18, 19, 21, 23, 24 mutations of both RI 
subunits (RI or RI have been linked to distinct phenotypes: Inactivating PRKAR1A 
gene (RI) mutations cause deregulated PKAc activities. Distinct mutations in RI 
account for the generation of endocrine tumors and cortisol-producing adenomas as 
observed in a disorder called Carney Complex45-47, 49, 50. Specific PRKAR1A gene (RI) 
mutations impair cAMP-dependent PKA activation and cause hormone resistance as 
observed in the rare disease Acrodysostosis (a form of skeletal dysplasia) 25, 26. We 
showed that mutated RI subunits as found in Carney Complex patients (RI[R74C])50 
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and Acrodysostosis patients (RI[R335P], RI[R368X])26, 48 still interact with GPR161 
(Figure 4). Such an interaction would desensitize compartmentalized GPR161-PKA 
complexes for cAMP-activation in case of Acrodysostosis. In addition we showed that a 
point mutation in the PRKAR1B gene (RI[L50R]), which is associated with 
neurodegenerative diseases27, diminished PPI with GPR161. We speculate that such a 
dominant negative function of RI subunits would dramatically decrease the complex 
formation of wild type RI subunits involved in dimer formation with the AKAP-receptor. 
Therefore we recommend that this new and high affinity RI scaffolding function of GPR161 
needs to be considered in analyses of spatiotemporal cAMP-dynamics in diseases with 
PKA dysfunction. 
Recent evidence illustrated that localized GPR161 functions are associated with 
hedgehog signaling in the primary cilium34. Indeed, we showed in a model organism that 
GPR161 targets RI to the cilium. Primary cilia are platforms for seven-transmembrane 
spanning receptor cascades including the hedgehog-linked smoothened pathway (Smo), 
which antagonizes cAMP-signaling. GPR161 activities seem to be the long-sought factors 
for creating spatiotemporal controlled cAMP-gradients in the ciliary hedgehog signaling 
pathway55, 56. In the primary cilium compartment cAMP-elevating GPR161 activities 
negatively regulate hedgehog signaling. Interestingly, activation of the counteracting 
hedgehog pathway triggers the removal of GPR161 from the cilium34. Our discovery has 
considerable consequences for the cilium signaling: First, the AKAP motif embedded 
within the GPR161 tail recruits and compartmentalizes cAMP-sensing type I holoenzymes 
into the plasma membrane of the cilium. Second, hedgehog ligands antagonize ciliary 
pools of GPR161 and most probably also receptor-interacting PKA activities. Overall we 
believe that the ciliary signaling complex consisting of cAMP-sensing GPR161-PKA is the 
missing link to integrate cAMP levels, compartmentalized PKA activities, and 
counteracting Smo signaling. A variety of ciliary dysfunctions, termed ciliopathies have 
been described55, 57. Both, the involvement of spatiotemporal cAMP-dynamics and the 
integrity of GPR161-PKA complexes need to be considered in molecular analyses of 
selected ciliopathies. In this context the smoothened receptor, a key component of seven-
transmembrane receptors signaling in the primary cilium, is already a central target for 
cancer drug discovery efforts58. We assume that pharmacological targeting of the AKAP 
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and/or the receptor function of the G-alpha-s coupled GPR161 receptor is one strategy to 
redirect decontrolled cAMP signaling. We hypothesize that besides direct 
pharmacological perturbation of receptor or kinase activities the ubiquitination of receptor 
interacting RI subunits is a feasible and alternative approach for controlling GPR161-PKA 
localization and signaling. Praja2 has been recently identified to be the major E3 ligase 
for PKA RI subunit ubiquitination59. It has been shown that PKA activities enhance praja2 
mediated degradation of phosphotransferase inhibitory PKA RI subunits leading to 
enhanced PKAc activities59. We speculate that degradation of R subunits is an alternative 
direction to impact GPR161 signaling. Taken together, we propose that the binary 
GPR161-PKA complex is a compartmentalized signaling hub that directly integrates 
receptor-sensed input signals with spatiotemporal cAMP dynamics. So far GPR161 is the 
first GPCR shown to have an AKAP function. Given that GPCRs are the largest family of 
cell surface molecules involved in signal transmission, it would be surprising if GPR161 is 
the ‘lone wolf’ with AKAP function amongst more than 800 GPCRs in the human genome 
60. However, if this is the case then it would further emphasize its critical and kinase-
compartmentalizing receptor function.  
Figure legends: 
Figure 1: PKA phospho-protein interactome and GPR161:RI interaction. a, Phospho-
proteins of affinity-purified PKA complexes are listed. A total of 127 phosphorylated amino 
acid residues isolated using PKA selective cAMP-resin are indicated; underlining marks 
previously described p-sites; red labeling highlights PKA group sites with a 
phosphorylated RxxS/T sequence motif. Potential cAMP binding proteins are indicated 
(*). b, Schematic illustration of GPR161 trafficking and signaling. c, GST pulldown 
analyzes of endogenous PKA subunits from HEK293 cell lysates in the presence or 
absence of 5 mM cAMP using GST and GST-CT (GPR161-Carboxy-Terminus342-529) 
fusions. d, Spotted peptides (25 mers, 20 aa [amino acid] overlap) of GPR161-CT342-529 
were overlaid with recombinant RICoomassie Brilliant Blue staining is shown). 
Immunoblotting (IB) has been performed with a monoclonal anti-RI antibody. e, Helical 
wheel projection of the identified amphipathic helix (aa 452…469) and indication of the 
centered L465 aa. 
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Figure 2: Interactions of GPR161:RI in vitro and in silico. a, GST pulldown analyzes 
of recombinant RI in the presence or absence of 5 mM cAMP using indicated GST-CT 
fusions of GPR161 including the CT342-529-L465P mutant. b, Following bacterial co-
expression of hexa-histidin (his6) and s-tag tagged CT378-529 (wt and L465P) and untagged 
RI (schematics are shown) we purified complexes using Ni-NTA resin. A representative 
CBB stained gel from n=3 independent experiments is shown. c. Structure-based 
alignment of GPR161 with RI specific and dual specific AKAPs. Residues that are similar 
and bind the D/D domain hydrophobic groove are shown in red. Identity (*) and similarities 
(: .) are indicated. Leucins highlighted with a red box are shown in the structure model in 
f. d. Structural model of RI D/D domain in complex with GPR161-CT457-479 peptide. 
Crystal structure of RI D/D domain in complex with DAKAP-2 peptide (PDB accession 
number 3IM4) was used to build the model in PyMol. The DAKAP-2 sequence was 
substitute with predicted amphipathic helix sequence of GPR161-CT457-479.  Side and top 
view of the model are shown. The monomers of the RI D/D domain are depicted in gold 
and yellow and the GPR161 helix is shown in red. The GPR161 residues that dock onto 
the hydrophobic groove formed by the two RI monomers are represented as surfaces. 
e. Direct binding of full-length RI (●) or full length RII (■) to FAM-labeled amphipathic 
helix of GPR161 (excitation at 535mm and emission at 580nm) by steady-state 
fluorescence anisotropy measurements. Shown is the amalgamated data from n=3 
independent experiments. KD value: 6.039 nM (±0.105). d. Model of RIa D/D domain in 
complex with GPR161 (457-479): Enlarged elements of GPR161 (L459 [part of the N-cap] 
and L477 [part of the C-cap]) interact with disulfide bridges from D/D RI subunits.  
Figure 3: Compartmentalization and phosphorylation of GPR161:RI complexes. a. 
Schematic illustration of GPR161 with the phosphorylation site and the core AKAP motif 
(with the centered LAKAI sequence) located in the CT. b. Immunoprecipitation of Venus-
YFP tagged GPR161 variants expressed in HEK293 cells following treatments with 
Forskolin (20 µM, 10 min) and Isoproterenol (1 µM, 10 min). Densitometry was used to 
quantification average changes of GPR161 phosphorylation (n=4 independent 
experiments, ±SEM). We used a phospho-(K/R)(K/R)X(S*/T*) specific antibody to analyze 
PKA phosphorylation [*] (Cell Signaling; #9621). IB from RI is from a different experiment 
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(it shows a better separation of antibody and RI). c. Subcellular localization of Venus-YFP 
tagged GPR161 fusion proteins in HEK293 cells. d. Subcellular localization of 
coexpressed mCherry-tagged GPR161 variants (wild type, L465P, SS429/430AA) and 
GFP-tagged RI in HEK293 cells. e. Sequence alignment of the GPR161 CT and 
localization of GFP-tagged RI and mCherry-tagged GPR161 in sections from zebra fish 
embryos. f. Quantification of cilia showing co-localizations of GPR161 variants and RI. 
Figure 4: Altered PPI of GPR161 variants with wild type and mutated RI. a. Schematic 
illustration of the Rluc-PCA biosensor strategy to quantify PPI of wild type and mutated 
GPR161 and RI in vivo. b. Impact of L465P mutation of GPR161-F[1]/[2] on complex 
formation with RI-F[1]/[2] (±SEM; representative of n=3).  c. Impact of the L50R disease 
mutation found in neurodegenerative diseases on RI:GPR161 interaction measured 
using the Rluc PCA (±SEM; representative of n=3).   d. Impact of patient mutations from 
Acrodysostosis (R335P, R368X) and Carney complex (R74C) patients on binary 
interaction with GPR161-F[2] (±SD; average of n=3 independent experiments). e. The 
effect of increasing isoproterenol (15 min) concentrations on PKA complex formation 
using indicated Rluc PCA expression vectors has been determined using transiently 
transfected HEK293 cells stably expressing the 2AR (average of n=4 independent 
experiments, ±SEM). 
 
Supplementary information. 
Supplementary Figure 1: Strategy to isolate endogenous PKA complexes using a 
PKA specific cAMP-agarose resin. a. Structure of Rp-8AHA-cAMP agarose. b. Flow 
chart of the proteomics and phospho-proteomics approach. Affinity-isolated PKA 
complexes from U2OS cells were analyzed using LC-MS/MS followed by semi-
quantitatively interrelationship analyses. c. Selective enrichment of endogenous PKA 
subunits from the osteosarcoma cell line U2OS. As negative control, we added excess of 
cAMP to mask cAMP-binding sites in R subunits for precipitation. Potential AMP binders 
are indicated (*). 
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Supplementary Figure 2: PPI network emanating from PKA. Following phospho-
proteomic analyses using LC-MS/MS, we generated a static PPI network of the confident 
set of PKA interacting proteins. We neglected applied pharmacological applications for 
the construction of the macromolecular PKA PPI network. Dark lines indicate known 
interactions. Triangles indicate identified phosphopeptides; circles indicate identified 
peptides; squares indicate identified peptides and phosphopeptides from the same protein 
or protein isoform. 
Supplementary Figure 3: Biochemical interaction studies of GPR161 and PKA. a. 
GST pulldown analyzes of endogenous PKA subunits from HEK293 cell lysates in the 
presence or absence of 5 mM cAMP using GST and GST-CT variants. b. cAMP-
precipitation of endogenous PKA complexes and overexpressed GPR161 variants tagged 
with Venus-YFP using two types of cAMP agarose. We have enriched PKA holoenzyme 
complexes using Rp-8-AHA-cAMP and activated PKA regulatory complexes using 8-AHA-
cAMP. In the negative control experiment we added excess of cAMP (5 mM) to the lysates 
to mask the cAMP binding sites in the R subunits for precipitation.  
Supplementary Figure 4: Bacterial expression and interaction analyzes of GPR161-
CT and RI. Following bacterial co-expression of hexa-histidin (his6) and s-tag tagged 
CT378-529 (wt and L465P) and untagged RI (schematics are shown) we purified 
complexes using Ni-NTA resin. Subsequently to imidazol elutions CT378-529 bound 
complexes have been subjected to cAMP precipitations (± excess of cAMP; 5 mM). 
Supplementary Figure 5: AKAP-peptide:RI interactions. Spotted peptide sequences 
directly derived from amphipathic helices of indicated AKAPs or in silico designed 
peptides39, 61 (25 mers, 20 aa [amino acid] overlap) were overlaid with recombinant RI. 
We have integrated proline mutations to control RI binding. Immunoblotting (IB) has 
been performed with a monoclonal anti-RI antibody. 
Supplementary Figure 6: Amphipathic helix and RII specific AKAPs. a. Helix 
propensity prediction of GPR161 were measured with AGADIR - an algorithm to predict 
the helical content of peptides. b. Structure-based alignment of RII specific AKAPs. 
Residues that are similar and bind the D/D domain hydrophobic groove are indicated (:). 
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Supplementary Figure 7: Immunoprecipitation, phosphorylation and localization of 
of GPR161. a. Immunoprecipitation of Venus-YFP tagged GPR161 variants expressed in 
HEK293 cells (representative of n=3). b. Immunoprecipitation of Venus YFP tagged 
GPR161 variants expressed in HEK293 cells following treatments with Forskolin (20 µM, 
10 min; representative of n=3). We used a phospho-(K/R)(K/R)X(S*/T*) specific antibody 
to analyze PKA phosphorylation [*] (Cell Signaling; #9621). c. Subcellular localization of 
Venus-YFP tagged GPR161 fusion proteins in HEK293 cells.  
Supplementary Figure 8: Impact of Forskolin on PPI of GPR161 dimers and 
GPR161:RI. Following coexpression of indicated Rluc PCA tagged constructs in 
HEK293 cells and subsequent Forskolin exposure (15 min, 20µM) bioluminescence 
signals have been quantified using the Rluc PCA as read out. 
Supplementary table 1.  Summary of peptides and phosphopeptides from the 
phospho-proteomics analyses (on the following 7 pages).  
 
 
Methods. 
Cell culture and antibodies. HEK293 and U2OS cells were grown in DMEM 
supplemented with 10% FBS. Transient transfections were performed with Transfectin 
reagent (Biorad). Cells were treated with Forskolin (Biaffin) or Isoproterenol (Sigma) with 
indicated concentrations and for the indicated time frames. Primary antibodies used were 
mouse anti-PKAc (BD Bioscience, #610981), anti-RIIβ (BD Bioscience, # 610626),  anti-
RI (BD Bioscience, #610166), anti-Rluc antibodies (MAB4400 versus Rluc-F(2), 
MAB4410 versus Rluc-F(1); Chemicon), anti-GST (Sigma, # G1160), anti-GFP (Roche, 
#11814460001) anti-GPR161 (Abcam, #83007; worked just with recombinant proteins), 
and a phosphospecific antibody to analyze PKA phosphorylation [*; (K/R)(K/R)X(S*/T*)] 
(Cell Signaling; # 9621).  
cAMP-agarose protein precipitation assay. We isolated endogenous protein 
complexes from U2OS cells under five conditions: for baseline binding and control of 
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binding specificity, without stimulation (i) and in the presence of excess of cAMP (ii), 
respectively. In parallel we performed PKA isolations following Forskolin stimulation for 
ten minutes (iii) and Isoproterenol for ten minutes (iv) and 24 hours (v). Following 
treatment with Forskolin (50 µM; 10 min) or Isoproterenol (10 µM; 10 min, 24 h [twice: at 
the time points 0 and 12 hour]) U2OS cells were homogenized using a Potter S (B. Braun 
Biotech International) with 15 strikes (standard lysis buffer: 10 mM sodium phosphate pH 
7.2, 150 mM NaCl, 0.5% Triton-X100 supplemented with standard protease inhibitors and 
phosphatase inhibitors). We clarified the lysate (13 000 rpm, 15 min) and precipitated 
endogenous PKA regulatory subunit associated protein complexes with PKA selective Rp-
8-AHA-cAMP agarose resin (Biolog, #A012) for two hours at 4°C. As negative control 
experiment we added excess of cAMP (1 mM) to the lysates to mask the cAMP binding 
sites in the R subunits for precipitation. Resin associated proteins were washed four times 
with standard lysis buffer and eluted with 1% SDS. Following SDS removal (using SDS 
removal columns; Calbiochem, # 263454) we analyzed the proteomic and phospho-
proteomic composition of bead associated complexes as previously described 62. We 
followed the same cAMP-precipitation protocol following transient overexpression of 
GPR161 variants in HEK293 cells. This time resin associated proteins were subjected to 
SDS-polyarylamid gel electrophoresis followed by immunoblotting. 
 
LC-MS/MS analyses. We were interested in both protein identity and protein 
phosphorylation: therefore we split the samples (83-250 µg each) and enriched 80% of 
the trypsin-digested material with titanium dioxide for phospho-peptide identification. The 
remaining 20% of the isolated material was used for the identification of bound proteins 
using LC-MS/MS. All experiments were performed as independent experiments and/or as 
independent triplicates. Tryptic digests and enriched phosphopeptides were analyzed on 
the LTQ-Orbitrap XL mass spectrometer (Thermo Fischer Scientific) coupled to a nano-
flow LC system (Eksigent). Peptides were first trapped on a reverse-phase pre-column 
(4mm length, 360 mm i.d.) and then separated on the analytical column (10 cm length, 
150 mm i.d.) (Jupiter C18, 3mm, 300 Angstrom (A°), Phenomenex) using an acetonitrile 
gradient ranging from 2 to 33% over 53 min at 600 nL/min. MS instrument was operated 
with the nano-electrospray source voltage set to 1.7 kV, MS scan resolution to 60 000 
(lock mass activated) and CID MS/MS spectra were acquired on data-dependent 
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acquisition mode for the three most abundant precursor ions (5 000 counts intensity 
threshold) 62. 
 
MS data processing. Acquired MS/MS spectra were pre-processed with Mascot Distiller 
v2.1.1 (Matrix Science) and the generated MGF files were searched with Mascot 2.1 on a 
concatenated target/decoy IPI human database v3.37 (34 584 protein sequences). 
Search parameters were as follow: precursor mass tolerance ±10 p.p.m., peptide 
fragment mass tolerance ±0.5Da, trypsin (two missed cleavages), and these variable 
modifications: carbamidomethyl (C), deamidation (NQ), oxidation (M), phosphorylation 
(STY). ProteoConnections, our in house bioinformatics software for phosphoproteomics 
analysis, was used to limit peptide FDR to 1%, to assess phosphorylation site localization 
confidence and to annotate previously reported phosphorylation sites. High abundant 
proteins were removed from the data (i.e. > 400000 copies per cell) 63, then label-free 
quantification of peptides was performed 62, 64. Programs were implemented in Python1, 
with some analyzes conducted with R2. 
Motif detection. We searched motifs with motif-x and we pre-aligned our identified 
phosphosites with a width of 15 amino acids as input and the IPI human proteome as 
background data 65. 
 
In vitro protein binding assays. We cloned coding regions of indicated aa stretches of 
the GPR161-CT (murine, ABO93465.1) into the pGEX-5X1 vector using flanking 
EcoRI/XhoI restriction sites. All GST-hybrid proteins were expressed in Escherichia coli 
(strains: BL21-DE3-RIL, Rosetta pLysS). Induction, cell lysis and affinity purification of 
hybrid proteins were performed as recommended by the supplier of the pGEX vectors (GE 
Healthcare). GST hybrid proteins (GST, GST-CT variants) immobilized on glutathione 
beads were incubated with cell lysates from HEK293 cells (DMEM medium supplemented 
with 10% FBS) for three hours. Resin-associated complexes were washed at least four 
times with the standard lysis buffer (10 mM sodium phosphate pH 7.2, 150 mM NaCl, 
0.5% Triton X100) and eluted with Laemmli sample buffer (2% SDS, 50 mM Tris HCl pH 
6.8, 0.2 mg/ml bromphenol blue, 0.1 M DTT, 10% (v/v) glycerol). 
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Protein expression and purification. To obtain the prokaryotic expression vectors 
pET11d-RIα-his6 and pET11d-RIα the human coding region (PKA RIα, NP 002725.1) was 
PCR-amplified using oligonucleotides with or without the C-terminal his6-tag followed by 
insertion into the multiple cloning site of the pET11d vector (Stratagene). Expression of 
recombinant proteins was performed in the Escherichia coli strain Rosetta pLysS 
(Novagen) at 30°C for 6 hours in LB medium. We purified PKA RIα-his6 protein by affinity 
chromatography according to supplier’s instructions for the Ni-NTA spin kit (Qiagen) 
followed by a size exclusion chromatography using an ÄKTA Superdex-75 gel filtration 
column (GE Healthcare). To obtain the double-his6 tagged prokaryotic expression vector 
construct pET30a-GPR161-CT378-528, the murine coding region (GPR161, ABO93465.1) 
was PCR-amplified followed by insertion into the multiple cloning site (BglII/XhoI) of the 
pET30a vector (Novagen). The L465P mutations was inserted via site directed 
mutagenesis. Co-expression of untagged RI and his6-CT378-528-his6 proteins were 
performed in Escherichia coli strain BL21-DE3-RIL at 30°C for 3 hours (1 mM IPTG) in LB 
medium containing both ampicillin and kanamycin antibiotics. Subsequently, the co-
expressed proteins (RIα and his6-CT378-528-his6) were affinity purified according to 
supplier’s instructions for the Ni-NTA agarose (Qiagen) and subjected to SDS-
polyacrylamide gelelectrophoresis. 
SPOT synthesis and overlay experiments. Overlapping peptides of GPR161-CT or i or 
indicated peptides containing substitutions of conserved amino acids in the different AKAP 
sequences were SPOT-synthesized (synthetic peptide arrays on membrane supports) on 
distinct coordinates of a cellulose membrane (starting from the N-terminus of the selected 
protein - C terminus of the GPCRs - with amino acid 1-25 [coordinate A1], amino acid 6-
30 [coordinate A2], etc.) 38. Membranes equilibrated in TBST buffer (10 mM Tris, 150 mM 
NaCl, 0,05% Tween 20, pH 7,4) were overlaid with recombinant RI (TBST supplemented 
with 5% non-fat dry milk). Interactions were detected with mouse anti-RI and secondary 
horseradish peroxidase antibodies by a procedure identical to immunoblotting (IB).  
Structural Docking. Crystal structure of RI dimerization and docking D/D domain 
(residues 13-62) in complex with Dual specific AKAP 2 (D-AKAP2) (PDB accession 
number 3IM4)41 was used to predict how the amphipathic helix sequence of GPR161-
CT457-479    will dock onto RIa D/D domain. DAKAP-2 sequence was substitute with 
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GPR161-CT457-479 sequence (SLDSYAASLAKAIEAEAKINLFGEE) The model and the 
figures were generated in PyMol.  
Fluorescence polarization. Full length PKA RI and PKA RII were purified as described 
previously66, 67. The 5- FAM N-terminal tagged GPR161 peptide 
(SLDSYAASLAKAIEAEAKINLFGEE), synthesized at NeoScientific (Cambridge, MA) and 
was dissolved in 100% DMSO. Serial dilutions of concentrated stocks of either RIa or RIIb 
purified proteins were prepared by diluting the proteins with the peptide in buffer A (10mM 
Hepes pH 7.4. 150mM NaCl, 3mM EDTA, 0.005% Surfactant P20). The final 
concentration of the peptide was 2nM. Samples were equilibrated for 10min or 1 hour at 
25°C with no significant change in anisotropy signal observed for up to 1hour after sample 
preparation. Flat bottom black 96-well plates (Thermo) were used and the peptide was 
excited (535nm) and emission was monitored (580nm) by Tecan Genios Pro 96/384 
Multifunction Microplate Reader (Tecan). Three separate binding experiments were 
averaged and fit to the non-linear regression model in GraphPad Prism version 6.0.   
Zebra fish. Pia. 
Immuno-precipitation. Following transient overexpression of indicated GPR161 variants 
tagged with Venus YFP we treated the cells either with Forskolin or Isoproterenol for 
indicated time frames.  Subsequent to PBS washing steps we homogenized them using 
a Potter S (B. Braun Biotech International) with 15 strikes (standard lysis buffer: 10 mM 
sodium phosphate pH 7.2, 150 mM NaCl, 0.5% Triton-X100 supplemented with standard 
protease inhibitors and phosphatase inhibitors). We clarified the lysate (13 000 rpm, 15 
min) and performed immunoprecipitations using ProteinA/G mixtures and 2 µg of control 
and anti-GFP antibodies for three hours at 4°C. Resin associated proteins were washed 
four times with standard lysis buffer and eluted with Laemmli sample buffer. 
Imaging. Life cell imaging have been performed using a Leica TCS SP5 II inverse laser 
scanning microscope. The settings for co-localization experiments were as followed: 
Johanna Even following single transient transfections (24h, 48h) we examined both 
mCherry and GFP fluorescence to control specificity of excitation and emission.  
GPR161 is a type I AKAP 
Page 22 of 26 
 
Renilla luciferase PCA. The Rluc PCA based hybrid proteins RIIb-F[1] and PKAc-F[2] 
have been designed as previously described 68. Rluc PCA fusions GPR161 have been 
generated using an analogous cloning approach. Following PCR amplification of the of 
the GPR161 gene we fused them C-terminally with either -F[1] or -F[2] of the Rluc PCA. 
PKA subunits and PKI were subcloned into the 5`end the 10aa linker (GGGGS)2 and the 
Rluc PCA fragments (pcDNA3.1 backbone vector). We generated the different mutants 
(RI; GPR161) using site directed mutagenesis. HEK293 cells were grown in DMEM 
supplemented with 10% FBS. We transiently overexpressed indicated versions of the 
Rluc-PCA based biosensor in 24 well plate format. 24 or 48 hours post-transfection we 
exchanged growth medium and resuspended cells in PBS. Cell suspensions were 
transferred to 96-well plates and subjected to bioluminescence analysis using the 
LMaxTMII384 luminometer (Molecular Devices). Rluc bioluminescence signals were 
integrated for 10 seconds following addition of the Rluc substrate benzyl-coelenterazine 
(5 µM; Nanolight). 
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